Ondansetron hydrochloride (HCl), a 5-HT3 receptor antagonist, is widely utilized to prevent nausea and vomiting, particularly in chemotherapy patients. Despite its therapeutic efficacy, its brief biological half-life and first-pass metabolism limit its bioavailability through conventional routes. Transdermal drug delivery offers a controlled and sustained release profile, thereby improving adherence to therapy. This review explores diverse strategies for the development and analysis of Ondansetron HCl transdermal patches, with a focus on polymer selection, film-forming techniques, and physicochemical property evaluation.
Oral and injectable forms of Ondansetron HCl, though effective, often necessitate multiple dosing and are associated with gastrointestinal or parenteral drawbacks. Transdermal systems can bypass hepatic first-pass metabolism and offer steady plasma drug levels. The development of patches involves multiple formulation variables, including drug-polymer interactions, release enhancers, and matrix design.
Transdermal Patch
Transdermal patches represent a sophisticated drug delivery system that administers drug through the skin, ensuring controlled and sustained release into systemic circulation. They are part of the broader category known as Transdermal Drug Delivery Systems (TDDS).
- Non-invasive: Avoids the gastrointestinal tract and first-pass hepatic metabolism.
- Controlled Release: Provides sustained or controlled drug delivery over hours or days.
- Improved patient compliance: especially advantageous for chronic conditions.
- Basic components of a transdermal patch are:
Reference
- Vyas S.P., Khar R.K., Controlled Drug Delivery-Concepts and Advances, 1 st Edition, Vallabh Prakashan, 2002, 411- 445
- Jain NK (2001) Controlled and novel drug delivery. (1st Edn.) CBS Publisher and Distributors, New Delhi, India 2001: 100-129.
- Dhiman S, Thakur G, and Rehni A: Transdermal patches: A recent approach to new drug delivery system. International Journal of Pharmacy and Pharmaceutical Sciences., 2011; 3: 26-34.
- Morrow DIJ, McCarron PA, Woolfson AD, and Donnelly RF: Innovative strategies for enhancing topical and transdermal drug delivery. The Open Drug Delivery Journal., 2007; 1: 36-59.
- Tortara GJ, Bryan H. Derrickson (2011) Principles of Anatomy and Physiology, (9th Edn.) 140-94.
- David SRN, Rajabalaya R, Zhia ES. Development and in vitro evaluation of selfadhesive matrix-type transdermal delivery system of ondansetron hydrochloride. Trop J Pharm Res. 2015;14(2):211–8.
- Bhardwaj S, Bhatia S, Singh S. Transdermal Delivery of Ondansetron Hydrochloride in the management of Hyperemesis Gravidarum. Int J Pharma Sci Res. 2020;11(8):206–14.
- Misra, A.N. 1997. Controlled and Novel Drug Delivery. In: Jain NK, editors. Transdermal Drug Delivery. New Delhi, India: CBS Publisher and Distributor, pp. 100-101.
- Rajabalaya, R., Chen, D.S., David, S.R.N. 2013. Development of transdermal ondansetron hydrochloride for the treatment of chemotherapy-Induced nausea and vomiting. Trop. J. Pharm. Res. 12, 279-285.
- Mohd, F. Bontha, L.S., Bontha, V.K., Vemula S.K. 2017. Formulation and evaluation of transdermal films of ondansetron hydrochloride. MOJ Bioequiv Availab. 3, 86-92.
- Makoto, S.; Sierra, C.; Naoko, N.; Marina, E.; Alan, Y.; Ruxandra-Ioana, A.; Evelina, P.; Paolo, C.; Ken, Y.; Jason, H.; & Kazuyoshi, A. (2025). Effect of Ondansetron and Metoclopramide on postoperative nausea and vomiting in children undergoing tonsillectomy with or without adenoidectomy: a systematic review with meta- analysis. Journal of Anaesthesia, Vol. 39, pages 345-354, print ISSN 0913-8668 (e-ISSN) is 1438-8359
- Chilkoti, Geetanjali T; Nandanan, Janaki; Saxena, Ashok Kumar; Seth, Varun; Kaur, Navneet1; Maurya, Prakriti. Low dose ondansteron with dexamethasone for prophylaxis of postoperative nausea and vomiting following laparoscopic cholecystectomy- A randomized double-blind study. Journal of Anaesthesiology Clinical Pharmacology, Vol. 41, No.1, (Jan-Mar 2025), pp. 84-89, Print ISSN: 0970-9185 Online ISSN: 2231-2730
- Sunita N. Vaidya, “Innovations in Topical Drug Delivery: Recent Developments in Transdermal Formulations, Gels, and Patches as Topical Medication Delivery Methods”, AJP, vol. 18, no. 04, Dec. 2024. Print ISSN: 0973-8398, Electronic ISSN: 1998-409X
- Patel M, Patel A, Desai J, Patel S. Cutaneous Pharmacokinetics of Topically Applied Novel Dermatological Formulations. AAPS Pharm SciTech. 2024 Feb 27;25(3):46. doi: 10.1208/s12249-024-02763-4. PMID: 38413430. ISSN (Print): 1530-9932, ISSN (Online): 1530-9932
- Suksaeree, J., Maneewattanapinyo, P., Panrat, K. et al. Solvent?Cast Polymeric Films from Pectin and Eudragit® NE 30D for Transdermal Drug Delivery Systems. J Polym Environ 29, 3174–3184 (2021). https://doi.org/10.1007/s10924-021-02108-3, ISSN (Print): 1566-2543, ISSN (Online): 1572-8919
- Kailash Sahu, Saman Pathan, Kapil Khatri, Neeraj Upmanyu and Satish Shilpi Development, Characterization, In Vitro and Ex Vivo Evaluation of Antiemetic Transdermal Patches of Ondansetron Hydrochloride and Dexamethasone GSC Biological and Pharmaceutical Sciences, 2021, 14(03), 067-078.
- Bharathi, D., Reddy, C. S., Babu, G., & Shirisha, Y. (2017). Formulation and Evaluation of Ondansetron HCl Transdermal Patch. World Journal of Pharmaceutical Research, 6(16), 417–426.
- Mohd, F., Bontha, L. S., Bontha, V. K., & Vemula, S. K. (2017). Formulation and evaluation of transdermal films of ondansetron hydrochloride. MOJ Bioequivalence & Bioavailability, 3(4), 00039.
- Teodorescu, F., Queniat, G., Foulon, C., & Szunerits, S. (2017). Transdermal skin patch based on reduced graphene oxide: A new approach for photothermal triggered permeation of ondansetron across porcine skin. Journal of Controlled Release, 245, 137–146.
- David, S. R. N., Rajabalaya, R., & Zhia, E. S. (2015). Development and in vitro evaluation of self-adhesive matrix-type transdermal delivery system of ondansetron hydrochloride. Tropical Journal of Pharmaceutical Research, 14(2), 211–218
- Swain, K., Pattnaik, S., Sahu, S. C., & Mallick, S. (2009). Feasibility assessment of ondansetron hydrochloride transdermal systems: Physicochemical characterization and in vitro permeation studies. Latin American Journal of Pharmacy, 28(5), 706–714.
- Formulation and Evaluation of Transdermal Ondansetron Hydrochloride Matrix Patch: In Vitro Skin Permeation and Irritation Study." International Journal of Pharmaceutical Research and Allied Sciences, vol. 13, no. 4, 2024
- Pattnaik, S., Swain, K., Mallick, S., & Lin, Z. (2011). Effect of casting solvent on crystallinity of ondansetron in transdermal films. International Journal of Pharmaceutics, 406(1–2), 106–110.
- Fathima, F., Kumar, V. B., Rudrangi, S. R. S., Vemula, S. K., Garrepally, P., & Chilukula, S. (2011). Formulation and evaluation of matrix-type transdermal delivery system of ondansetron hydrochloride using solvent casting technique. Research Journal of Pharmacy and Technology, 4(5), 806–814
- Alok Ranjan, Aishwarya Sahu, Akansha Yadav, Alka Payasi, Akash Jaiswal, Akshay Kumar, Akash Sahu, Ashwani Jangde, Chandrashekhar Nayak, Dev Kumar, Harshita Yarda, Mitali Sahu, Nokesh Sahu, Rajesh Patel, Nisha Nair, Mukta Agrawal, Ajazuddin, D. K. Tripathi, Amit Alexander. A Short Review on the Formulation of Transdermal Dermal Drug Delivery System (TDDS). Res. J. Pharma. Dosage Forms and Tech. 2018; 10(2): 90-94.
Bhawna Sirohi
Corresponding author
HIMT College of Pharmacy, 08, Knowledge Park-1, Greater Noida, Distt. Gautam Buddh Nagar (U.P.)-201310
Hema Negi
Co-author
HIMT College of Pharmacy, 08, Knowledge Park-1, Greater Noida, Distt. Gautam Buddh Nagar (U.P.)-201310
Bhawna Sirohi*, Hema Negi, A concise review on Development and Assessment of Ondansetron Hydrochloride-Loaded Transdermal Patches, Int. J. Sci. R. Tech., 2025, 2 (6), 631-637. https://doi.org/10.5281/zenodo.15722037
10.5281/zenodo.15722037